The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Exclusion Criteria

• •1. received TKIs drug treatment before enrollment
• •2. Central nervous system leukemia
• •3. Previous anti-CML therapy over two weeks (hydroxyurea, except anagrelide) or surgery (including hematopoietic stem cell transplantation)
• •4. Cardiac dysfunction
• •5. Previous splenectomy
• •6. History of congenital or acquired bleeding disorders unrelated to CML
• •7. Previous malignancy except CML
• •8. Acute or chronic liver or severe kidney disease unrelated to CML
• •9. Pregnant, breastfeeding, child bearing potential but failed to take effective contraception